NCI Dictionary of Cancer Terms - NCI
Neuroendocrine Tumor Treatment Market: Trends, Growth Drivers, And Forecast By 2030 – Reports And Data
The MarketWatch News Department was not involved in the creation of this content.
Apr 23, 2023 (Heraldkeepers) -- During the forecast period, the Global Neuroendocrine Tumor Treatment Market is anticipated to witness a rapid increase in revenue CAGR. This can be attributed to the rising demand for available therapies and the introduction of new diagnostic tools. Neuroendocrine tumor is a rare form of cancer that originates in specialized cells called neuroendocrine cells. These cells share characteristics with nerve and hormone-producing cells. This type of tumor can occur in various parts of the body such as the pancreas, lungs, small intestine, rectum, and appendix. When the DNA of healthy cells is damaged, they begin to transform and multiply uncontrollably, forming an aggregate of cells which is the starting point of a tumor. Tumors can be either malignant or benign. If a malignant tumor is not detected and treated early, it can grow and spread to other parts of the body. On the other hand, a benign tumor may grow but won't spread, and minimally invasive surgery can typically be used to remove it.
Request Sample of These Report @ https://www.Reportsanddata.Com/download-free-sample/5580
Functional neuroendocrine tumors are those that produce excessive hormones, while non-functional neuroendocrine tumors are those that do not produce enough hormones to cause symptoms. Some of the symptoms associated with these tumors include pain from growing tumor, lump under the skin, fatigue, and weight loss. The growing prevalence of cancer has resulted in a heightened demand for effective treatment options. As a result, global companies are investing a significant portion of their revenue in research and development to create advanced drugs. Numerous pharmaceutical products that use sophisticated delivery systems are in the process of being approved by the FDA. The market's growth is largely fueled by the rising demand for state-of-the-art medications that can effectively treat neuroendocrine tumors.
Key Players Operating in Neuroendocrine Tumor Treatment Market
Driving Factor in Neuroendocrine Tumor Treatment Market
Neuroendocrine Tumor Treatment Market: Notable Innovations
The global Neuroendocrine Tumor Treatment Market has been segmented as follows:
Disease Type Outlook
Location of Tumor Outlook
Grade of Tumor Outlook
Treatment Type Outlook
Product Type Outlook
By Distributional Channel Outlook
By Route of Administration Outlook
By End-user Outlook
Regional Outlook
Request a customization of the report @ https://www.Reportsanddata.Com/request-customization-form/5580
Thank you for reading global Neuroendocrine Tumor Treatment Market report. We also offer customized research reports as per client requirement. Kindly contact us to know more about the feature and our team will provide you a well-curated report in the stipulated time.
Explore more trending reports:
Biopharmaceutical Excipients Market – https://www.Reportsanddata.Com/report-detail/biopharmaceutical-excipients-market
Cell Gene Therapy Manufacturing Market – https://www.Reportsanddata.Com/report-detail/cell-gene-therapy-manufacturing-market
Dental Laboratory Market – https://www.Reportsanddata.Com/report-detail/dental-laboratory-market
About Us:Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.
Contact Us:
John W
Head of Business Development
Reports And DataWeb: www.Reportsanddata.Com
Direct Line: +1-212-710-1370
E-mail: sales@reportsanddata.Com
LinkedInTwitterBlogsInsights
COMTEX_429952014/2582/2023-04-23T07:19:28
Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.Com. You can also contact MarketWatch Customer Service via our Customer Center.
The MarketWatch News Department was not involved in the creation of this content.
Study Opens New Possibilities Of Tailoring Radiopharmaceutical Treatment To Neuroendocrine Cancer Patients
A simple blood draw can provide physicians with valuable information that can determine if peptide receptor radionuclide therapy (PRRT) is likely to be effective in a patient with neuroendocrine cancer. The blood-based biomarker PPQ can predict which patients will respond to PRRT with 96 percent accuracy; changes in another biomarker, NETest, correctly correlate with PRRT response in 90 percent of patients. The study, published in the April issue of The Journal of Nuclear Medicine, opens new possibilities of tailoring radiopharmaceutical treatment to patients.
While biomarkers have been used to predict the outcomes of treatments for breast, prostate, and other cancers, there are currently no objective means to predict the efficacy of radiopharmaceutical therapy for neuroendocrine tumors. "In previous studies our team introduced the blood-based biomarkers PPQ and NETest as a measure for determining whether treatment with PRRT would be successful," noted Lisa Bodei, MD, PhD, nuclear medicine physician at Memorial Sloan Kettering Cancer Center in New York, New York. "In this new study we sought to validate the role of PPQ and NETest in predicting response and monitoring PRRT."
Sixty-seven patients with somatostatin receptor-positive gastroenteropancreatic and lung neuroendocrine tumors were included in the study. All patients had metastatic disease and had received prior treatments. Blood samples were collected before each cycle of PRRT and at follow-up. PPQ was scored as either positive (likely to respond) or negative (unlikely to respond), and NETest was measured on a scale of zero to 100, with the upper limit of normality being 20.
Of the 67 patients in the study, 40 were classified as PPQ+, and 39 of them (98 percent) responded to PRRT. Twenty-seven patients were PPQ–, and 25 patients in this group experienced disease progression despite PRRT. The overall predictive accuracy of PPQ was 96 percent.
NETest was elevated in all patients prior to PRRT therapy. For PRRT responders, baseline NETest levels were 67, which decreased by 37 percent after treatment. For non-responders, baseline NETest levels were 44, which increased by 76 percent at follow-up. The NETest biomarker was 90 percent accurate for determining PRRT response.
The results of this study demonstrate that not all tumors are created equal; some are more prone to respond to PRRT, and some are less susceptible to radiopharmaceutical therapy. This is the reason why our research is important: to understand from the start which patients will require an intensified treatment plan and which patients, instead, can benefit from a lighter regimen will tremendously improve their management."
Lisa Bodei, MD, PhD, nuclear medicine physician, Memorial Sloan Kettering Cancer Center
This study was made available online in November 2022.
Source:
Journal reference:
Bodei, L., et al. (2022). Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of 177Lu-DOTATATE in Neuroendocrine Tumors. Journal of Nuclear Medicine. Doi.Org/10.2967/jnumed.122.264363.
Health Headlines: Injectable Radiation Used To Treat Neuroendocrine Cancer
© Provided by Lake Charles KPLC Health Headlines: Injectable radiation used to treat neuroendocrine cancerDENVER, Colo. (Ivanhoe Newswire) – NET cancer is short for neuroendocrine tumors. It's a type of cancer that is slow growing and can happen anywhere in your body. As with most cancers, treatment can start with surgery, chemo, and radiation. But now, doctors are using a very targeted, missile-like therapy to destroy the tiniest of these cancer cells.
Steve Jobs and Aretha Franklin both lost their battle to what most people thought was pancreatic cancer, but the real culprit of their cancer was neuroendocrine tumors.
Rocky Mountain Cancer Centers neuroendocrine cancer specialist, Eric Liu, MD says, "It can come from any part of your body, from your lungs, from your pancreas, from your intestines."
Symptoms can be varied and go misdiagnosed for years. In fact, 90 percent of neuroendocrine cancers are misdiagnosed.
"Just imagine if you had abdominal pain every six to 12 months," Dr. Liu says.
But some very common symptoms could be neuroendocrine cancer, that's what happened to Robert Hammer.
"I started coming up with this very itchy rash under my skin and I have a lot of seasonal allergies in Colorado, so that's what I maybe thought was happening," Hammer remembers.
But a scan revealed that Hammer had a tumor the size of an orange on his pancreas. Surgery to remove his pancreas was too risky. After several other therapies, including hormone therapy, Dr. Liu treated Hammer with a new injectable radiation called PRRT.
Dr. Liu explains, "The little hormone-guided missile takes it right to the tumor. The tumor absorbs the radiation. And the neat thing about it is the treatment goes to every single tumor in the body."
The radiation is given through an IV over several months. Before the radiation, Hammer was given eight to 12 years to live, now that number is 18 to 20 years.
"I count every day as joy," Hammer exclaims.
Studies show that on average, it takes five years from the onset of symptoms, for patients to get the right diagnosis and begin proper treatment. Using injectable radiation to treat it is just the beginning. Dr. Liu believes the PRRT will be used to treat prostate cancer, as well as other kinds of cancer in the near future.
Contributors to this news report include Marsha Lewis, Producer; Roque Correa, Videographer & Editor.
Comments
Post a Comment